1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Abdominal Obesity - Pipeline Review, H2 2013

Abdominal Obesity - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Abdominal Obesity - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Abdominal Obesity - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Abdominal Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abdominal Obesity. Abdominal Obesity - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Abdominal Obesity.
- A review of the Abdominal Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Abdominal Obesity pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Abdominal Obesity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Abdominal Obesity pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Abdominal Obesity - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Abdominal Obesity Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Abdominal Obesity 7
Abdominal Obesity Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Abdominal Obesity Therapeutics - Products under Development by Companies 12
Companies Involved in Abdominal Obesity Therapeutics Development 13
Theratechnologies Inc. 13
Aileron Therapeutics, Inc. 14
Lithera, Inc. 15
Abdominal Obesity - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
tesamorelin acetate - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
(fluticasone propionate + salmeterol xinafoate) - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
ALRN-5281 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
salmeterol xinafoate - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Abdominal Obesity Therapeutics - Drug Profile Updates 29
Abdominal Obesity - Product Development Milestones 33
Featured News and Press Releases 33
Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia 33
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 33
Apr 02, 2013: Lithera Receives Patent From USPTO Protecting Methods Of Use And Formulations For LIPO-202 34
Mar 12, 2013: Lithera Initiates Phase IIb Clinical Trial Of LIPO-202 Targeting Aesthetic Reduction Of Subcutaneous Abdominal Fat 34
Feb 26, 2013: Aileron Therapeutics To Highlight Stapled Peptide Pipeline At 2013 AsiaTIDES Meeting 35
Jan 21, 2013: Theratechnologies Announces FDA Approval Of Alternative Storage Conditions For Egrifta 36
Sep 06, 2012: Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C Chen As Vice President of Clinical Development 36
Jun 26, 2012: Ferrer Withdraws Marketing Authorization Application For Egrifta 37
Sep 06, 2011: GENFIT Publishes GFT505 Clinical Trial Results In Diabetes Care 37
Dec 06, 2010: Theratechnologies Announces A Distribution And Licensing Agreement For Egrifta In Latin America, Africa And The Middle East With Sanofi-aventis 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

Number of Products Under Development for Abdominal Obesity, H2 2013 7
Products under Development for Abdominal Obesity - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Theratechnologies Inc., H2 2013 13
Aileron Therapeutics, Inc., H2 2013 14
Lithera, Inc., H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Assessment by Combination Products, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 21
Abdominal Obesity Therapeutics - Drug Profile Updates 29



List of Figures

Number of Products under Development for Abdominal Obesity, H2 2013 7
Products under Development for Abdominal Obesity - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 16
Assessment by Combination Products, H2 2013 17
Assessment by Route of Administration, H2 2013 18
Assessment by Stage and Route of Administration, H2 2013 19
Assessment by Molecule Type, H2 2013 20
Assessment by Stage and Molecule Type, H2 2013 21



Companies Mentioned

Theratechnologies Inc.
Aileron Therapeutics, Inc.
Lithera, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Growth Hormone Secretagogue Recepto ...

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Obesity - Pipeline Review, H2 2016

November 2016 $ 2500

Download Unlimited Documents from Trusted Public Sources

CKD - Investor Report, December 2016

  • December 2016
    23 pages
  • Therapy  

    Therapy  

  • United States  

    World  

View report >

C&C Cosmeceuticals Corporation - Company Report, November 2016

  • November 2016
    2 pages
  • Managed Care  

    Healthcare  

    Chronic Disease  

  • United States  

    Canada  

    Europe  

View report >

C&C Cosmeceuticals Corporation - Company Report, November 2016

  • November 2016
    2 pages
  • Managed Care  

    Healthcare  

    Chronic Disease  

  • United States  

    Canada  

    Europe  

View report >

Related Market Segments :

Obesity

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.